Metal complexes with superoxide dismutase-like activity as candidates for anti-prion drug

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 23, 2006, Pages 5982-5987

  Fukuuchi, Tomoko ^a,b   Doh ura, Katsumi ^c   Yoshihara, Shin'ichi ^b   Ohta, Shigeru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

2,2 Biquinoline; Chelate; Cimetidine; Copper; Metal complex; Prion; SOD activity; TPEN

Indexed keywords

1,10 PHENANTHROLINE; 2,2' BICINCHONINIC ACID; 2,2' BIQUINOLINE; 2,2',2'' TERPYRIDINE; 2,9 DIMETHYL 1,10 PHENANTHROLINE; 8 QUINOLINOL; BATHOCUPROINE; BIS(8 QUINOLINOLATO)COPPER; BIS(8 QUINOLINOLATO)ZINC; COPPER COMPLEX; METAL CHELATE; METAL COMPLEX; PRION PROTEIN; PROTEINASE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

CELL LINE; CHELATING AGENTS; COPPER; MOLECULAR STRUCTURE; PRIONS; SPECTRUM ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP; SUPEROXIDE DISMUTASE;

EID: 33750521766     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.08.115     Document Type: Article

References (46)

1. Prusiner S.B. Science 216 (1982) 136
2. Bounias M., and Purdey M. Sci. Total Environ. 297 (2002) 1
3. Brown D.R., Qin K., Herms J.W., Madlung A., Manson J., Strome R., Fraser P.E., Kruck T., von Bohlen A., Schulz-Schaeffer W., Giese A., Westaway D., and Kretzschmar H. Nature 390 (1997) 684
4. Viles J.H., Cohen F.E., Prusiner S.B., Goodin D.B., Wright P.E., and Dyson H.J. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 2042
5. Jackson G.S., Murray I., Hosszu L.L., Gibbs N., Waltho J.P., Clarke A.R., and Collinge J. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 8531
6. Brown D.R., Wong B.S., Hafiz F., Clive C., Haswell S.J., and Jones I.M. Biochem. J. 344 (1999) 1
7. Brown D.R. J. Neurosci. Res. 58 (1999) 717
8. Pauly P.C., and Harris D.A. J. Biol. Chem. 273 (1998) 33107
9. McKenzie D., Bartz J., Mirwald J., Olander D., Marsh R., and Aiken J. J. Biol. Chem. 273 (1998) 25545
10. Brown D.R., Hafiz F., Glass-smith L.L., Wong B.S., Jones I.M., Clive C., and Haswell S.J. EMBO J. 19 (2000) 1180
11. Kimberlin R.H., Millson G.C., Bountiff L., and Collis S.C. J. Comp. Pathol. 84 (1974) 263
12. Pattison I.H., and Jebbett J.N. Nature 230 (1971) 115
13. Sigurdsson E.M., Brown D.R., Alim M.A., Scholtzova H., Carp R., Meeker H.C., Prelli F., Frangione B., and Wisniewski T. J. Biol. Chem. 278 (2003) 46199
14. Copper(II) perchlorate hexahydrate 98% and d-penicillamine were purchased from Sigma. Iron(II) sulfate heptahydrate, 2,2′-biquinoline, and cimetidine were purchased from Wako Pure Chemical (Osaka, Japan). 1,10-Phenanthroline monohydrate, 2,9-dimethyl-4,7-dimethyl-1,10-phenanthroline (bathocuproine), 2,9-1,10-phenanthroline (neocuproine), tetraphenylporphine (TPP), tetraphenylporphine tetrasulfonic acid (TPPS), α,β,γ,δ-tetrakis(1-methylpyridinium-4-yl)porphine p-toluenesulfonate (TMPyP), tetrakis(4-carboxyphenyl)porphine (TCPP), 2,2′-bicinchoninic acid dipotassium salt, 5-chloro-7-iodo-8-hydroxyquinoline (clioquinol), and 8-hydroxyquinoline were purchased from Tokyo Kasei (Tokyo, Japan). Manganese(III) tetrakis(1-methylpyridinium-4-yl)porphyrin pentachloride (Mn-TMPyP) and Mn(III)tetrakis(4-benzoic acid)porphyrin chloride(Mn-TCPP or Mn-TBAP) were purchased from Calbiochem (California, USA). They were dissolved in 100% dimethylsulfoxide (DMSO) or 95% ethanol just before use.
15. Two types of prion-infected mouse neuroblastoma (N2a) cell lines were used in this study: N2a cells infected with the RML strain (ScN2a) [16] and N2a#58 cells infected with the Fukuoka-1 strain (F3). N2a#58 cells are known to express five times more normal PrP than N2a cells. Both ScN2a cells and F3 cells were grown in six-well culture plates in Opti-MEM (Invitrogen) supplemented with 10% fetal bovine serum. The cells were allowed to reach confluence, and chemicals at various concentrations were added to the medium when 5% of the confluent cells were passaged.The final concentration of either DMSO or ethanol in the medium was less than 0.2%. The cultures were allowed to grow to confluence (3 or 4 days).
16. Milhavet O., McMahon H.E., Rachidi W., Nishida N., Katamine S., Mange A., Arlotto M., Casanova D., Riondel J., Favier A., and Lehmann S. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 13937
17. 18,19 Solutions of 10 mM Cu(II) and each compound at a compound:Cu (II) ratio of 1:0 to 0:1 were prepared in ultrapure water (MilliQ; Millipore Co., Japan) or 95% ethanol, and λmax of the copper complex was measured.
18. Vosburgh W.C., and Cooper G.R. J. Am. Chem. Soc. 63 (1941) 437
19. Job P. Ann. Chim. 9 (1928) 113
20. Kolthoff I.M.S., and Sandell E.B. Textbook of Quantitative Inorganic Analysis (1959), Pergamon Press, New York The MacMillan Co.
21. Ueno K., Imamura T., and Cheng K.L. Handbook of Organic Analytical Reagents (1992), Pergamon Press, Tokyo CRC Press
22. Birker P.J., and Freeman H.C. J. Am. Chem. Soc. 99 (1977) 6890
23. 50 of each compound.
24. Doh-Ura K., Iwaki T., and Caughey B. J. Virol. 74 (2000) 4894
25. Murakami-Kubo I., Doh-ura K., Ishikawa K., Kawatake S., Sasaki K., Kira J., Ohta S., and Iwaki T. J. Virol. 78 (2004) 1281
26. Ishikawa K., Doh-ura K., Kudo Y., Nishida N., Murakami-Kubo I., Ando Y., Sawada T., and Iwaki T. J. Gen. Virol. 85 (2004) 1785
27. Day B.J., Shawen S., Liochev S.I., and Crapo J.D. J. Pharmacol. Exp. Ther. 275 (1995) 1227
28. Day B.J., and Crapo J.D. Toxicol. Appl. Pharmacol. 140 (1996) 94
29. Younes M., Lengfelder E., Zienau S., and Weser U. Biochem. Biophys. Res. Commun. 81 (1978) 576
30. Kimura E., Sakonaka A., and Nakamoto M. Biochim. Biophys. Acta 678 (1981) 172
31. Kimura E., Yatsunami A., Watanabe A., Machida R., Koike T., Fujioka H., Kuramoto Y., Sumomogi M., Kunimitsu K., and Yamashita A. Biochim. Biophys. Acta 745 (1983) 37
32. Wada K., Fujibayashi Y., and Yokoyama A. Arch. Biochem. Biophys. 310 (1994) 1
33. Goldstein S., and Czapski G. Free Radic. Res. Commun. 12-13 (1991) 205
34. Baudry M., Etienne S., Bruce A., Palucki M., Jacobsen E., and Malfroy B. Biochem. Biophys. Res. Commun. 192 (1993) 964
35. Darr D.J., Yanni S., and Pinnell S.R. Free Radic. Biol. Med. 4 (1988) 357
36. Wada K., Fujibayashi Y., Tajima N., and Yokoyama A. Biol. Pharm. Bull. 17 (1994) 701
37. SOD-like assay kit-WST (Dojindo Chemical, Kumamoto, Japan) was used for the quantification of SOD-like activity. This method is a xanthine-based spectrophotometric assay using the tetrazolium salt WST-1. The SOD-like activity was evaluated using the standard curve of SOD-like activity versus absorbance at 450 nm. Differences of SOD-like activity were tested by use of the unpaired Student's t test, and p values smaller than 0.05 were considered to be statistically significant.
38. Kimura E., Koike T., Shimizu Y., and Kodama M. Inorg. Chem. 25 (1986) 2242
39. Nagano T., Hirano T., and Hirobe M. J. Biol. Chem. 264 (1989) 9243
40. Hijazi N., Shaked Y., Rosenmann H., Ben-Hur T., and Gabizon R. Brain Res. 993 (2003) 192
41. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., Kim Y., Huang X., Goldstein L.E., Moir R.D., Lim J.T., Beyreuther K., Zheng H., Tanzi R.E., Masters C.L., and Bush A.I. Neuron 30 (2001) 665
42. Martins V.R., Mercadante A.F., Cabral A.L., Freitas A.R., and Castro R.M. Braz. J. Med. Biol. Res. 34 (2001) 585
43. Rachidi W., Vilette D., Guiraud P., Arlotto M., Riondel J., Laude H., Lehmann S., and Favier A. J. Biol. Chem. 278 (2003) 9064
44. Rachidi W., Mange A., Senator A., Guiraud P., Riondel J., Benboubetra M., Favier A., and Lehmann S. J. Biol. Chem. 278 (2003) 14595
45. Li Q.X., Luo Q.H., Li Y.Z., and Shen M.C. Dalton Trans. (2004) 2329
46. Totte J., Scharpe S., Verkerk R., Neels H., Vanhaeverbeek M., Smitz S., and Rousseau J.J. Lancet 1 (1981) 1047